Drug Profile

Margetuximab - MacroGenics

Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MARGENZA; Margetuximab-cmkb; MGAH-22

Latest Information Update: 12 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Raven biotechnologies
Developer GC Biopharma; Green Cross; MacroGenics; Merck Sharp & Dohme; ZAI Lab
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Oesophageal cancer; Gastric cancer
New Molecular Entity Yes

Marketed HER2 positive breast cancer
Discontinued Bladder cancer; Gastric cancer; Haematological malignancies; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours

25 Mar 2025 MacroGenics completes a phase-II/III clinical trial in Gastric cancer and Oesophageal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China, Germany, Italy, South Korea, Poland, Singapore, Taiwan, UK and the US (IV) (NCT04082364)
10 Dec 2024 Efficacy and adverse events data from a phase II MARGOT trial in HER2-positive-breast-cancer presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
23 Oct 2024 TerSera Therapeutics in-licenses Margetuximab from MacroGenics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com